Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rocket Pharmaceuticals Inc.

http://www.rocketpharma.com/

Latest From Rocket Pharmaceuticals Inc.

Danon Disease Gene Therapy & TGCT Treatment Win EMA PRIME Designations

Promising early clinical trial results from Rocket and Abbisko respectively helped the companies secure their places on the European Medicines Agency’s priority medicines scheme, which aims to help speed up the development and regulatory review of treatments for unmet medical needs.

Review Pathway Europe

In Vivo’s 2023 Rising Leaders: Healthcare Innovators At The Top Of Their Game

The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.

Leadership Business Strategies

Rocket Pharmaceuticals’ CEO Talks Gene Platforms and Spiritual Leadership

The trajectory of Rocket Pharmaceuticals, a clinical-stage gene therapy company, has been marked by a series of impressive milestones. At least partial credit for those accomplishments goes to CEO Gaurav Shah, who co-founded the company in 2015 and has combined scientific, business and managerial savvy to progress the company through two regulatory filings this year. Shah recently spoke to In Vivo about the company and his own leadership style.

C-Suite Speaks Interviews

Sidestepping Gene Therapy ‘Land Grab’ Mistakes, Rocket Is Set For First Filings In 2023

While other gene therapy companies faced major clinical and financing problems in 2022, Rocket Pharma sidestepped some of these pitfalls and is gearing up for two US filings this year.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Inotek Pharmaceuticals
    • Renovacor Inc.
UsernamePublicRestriction

Register